Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $82.7 million.

  • Puma Biotechnology's Total Current Liabilities fell 2506.32% to $82.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.7 million, marking a year-over-year decrease of 2506.32%. This contributed to the annual value of $96.1 million for FY2024, which is 329.13% down from last year.
  • Puma Biotechnology's Total Current Liabilities amounted to $82.7 million in Q3 2025, which was down 2506.32% from $79.1 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Total Current Liabilities peaked at $140.4 million during Q1 2021, and registered a low of $48.2 million during Q1 2023.
  • In the last 5 years, Puma Biotechnology's Total Current Liabilities had a median value of $86.7 million in 2025 and averaged $89.8 million.
  • In the last 5 years, Puma Biotechnology's Total Current Liabilities plummeted by 5878.61% in 2022 and then soared by 10376.65% in 2024.
  • Over the past 5 years, Puma Biotechnology's Total Current Liabilities (Quarter) stood at $109.6 million in 2021, then fell by 29.29% to $77.5 million in 2022, then rose by 28.26% to $99.4 million in 2023, then fell by 3.29% to $96.1 million in 2024, then fell by 13.92% to $82.7 million in 2025.
  • Its Total Current Liabilities stands at $82.7 million for Q3 2025, versus $79.1 million for Q2 2025 and $86.7 million for Q1 2025.